in English

Yrityshakemisto

50 yritystä löytyi. = FIB jäsenyritys
Company	Contact information	Activities
AB Enzymes Oy PO Box 26, FIN-05201 Rajamäki, Finland Web site: www.abenzymes.com Founded: 1997 Turnover: EUR 2,2 million (2004) Personnel: 14 (2004)	Pentti Ojapalo, Textile Group Manager Phone: +358 9 2902 2515 Fax: +358 9 2902 2550 pentti.ojapalo at abenzymes.fi	R&D activities: Development of technical enzyme applications. Core technologies: Technical enzymes for use in following industrial areas of application: detergent, textile, pulp and paper, animal feed. Categories of activity: Biotech company; Production; R&D; Enzymes;
Alkomohr Biotech Oy Ltd Lehtotie 8, FIN-00630 Helsinki, Finland Founded: 1995 Personnel: 3	Dr Matti Korhola, Managing Director Phone: +358 50 562 6903 Fax: +358 9 728 3937 matti.korhola at yeast.pp.fi	R&D activities: Research, product and process development on industrial enzymes and yeasts. Core technologies: Baker's, brewer's, distiller's, sour dough, and wine yeast strain improvement by classical genetic breeding and by genetic engineering. Proprietary enzyme application technology. Categories of activity: Biotech support company; Other service; Enzymes;
Bayer Oy Bayer CropScience Suomalaistentie 7, FI-02270 Espoo, Finland Web site: www.bayercropscience.com Personnel: 1		Production (and other) activities: Markets crop protection products. Categories of activity: Biotech support company; Supplier; Agro;
Biocelex Oy Lemminkäisenkatu 5 C, FI-20520 Turku, Finland Web site: www.biocelex.com Founded: 2007 Turnover: EUR <1 M€ million (2008) Personnel: 3 (2007)	Kai Lahtonen, President & CEO Phone: +358 50 689 48 Fax: +358 2 4788 488 kai.lahtonen at biocelex.com	Production (and other) activities: Biocelex Ltd is a privately-held international innovation and business development company offering services for the Life Sciences field. We focus on business and technology areas related to drug discovery & development, diagnostics, biomaterials, functional foods and life science services. Geographically we operate in Scandinavia and the Baltic Sea region, with a particular focus on Finland. In terms of Innovation Development, Biocelex adapts and applies the world famous and proven process of one of its co-owners, Karolinska Institutet Holding AB. We evaluate, consult and develop promising innovation to start-ups with a possibility for early-stage funding from Karolinska Development AB fund. Biocelex Ltd offers Business Development services for a broad range of Life Science companies. For growth phase companies, our experienced team can help you with e.g. strategy and business planning, product development and market entry. For established companies looking for new openings or additions to their product portfolio, we offer e.g. scouting services, due diligence or technical assessments and reports on the local operating environment. Categories of activity: Biotech support company; Other service;
BioExpand Oy C/O Ovil Oy Korsintie 12, 01450 Vantaa Web site: www.bioexpand.fr Founded: 2005 Personnel: 1	Claude Lubicki, CEO Phone: +33 6 08 152652 Fax: claude.lubicki at bioexpand.fr	Production (and other) activities: BioExpand is an international Life Sciences Marketing and Business Development Consultancy. BioExpand particular focus is on offering services to Biotech / Pharmaceutical SMEs and BioClusters. BioExpand develops close cooperation with Private Equity and venture Capital firms as expert in its field Core technologies: Consulting Services Categories of activity: Biotech support company; Other service;
Biotie Therapies Oyj Tykistökatu 6, FI-20520 Turku, Finland Web site: www.biotie.com Founded: 1992 Turnover: EUR 5,6 million (2009) Personnel: 80 (2009)	Chris Piggott, Chief Business Officer Phone: +358 2 274 8900 Fax: +358 2 274 8910 chris.piggott at biotie.com Timo Veromaa, President & CEO Phone: +358 2 2748 901 Fax: +358 2 274 8 910 timo.veromaa at biotie.com	Production (and other) activities: Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany. Shares are listed on NASDAQ OMX Helsinki Ltd. R&D activities: Categories of activity: Biotech company; R&D; Drug discovery;
Biovian Oy Tykistökatu 6 B, FI-20520 Turku, Finland Web site: www.biovian.com Founded: 2003 Turnover: EUR 2.8 million (2009) Personnel: 30 (2009)	Knut Ringbom, Director Phone: Fax: knut.ringbom at biovian.com	Production (and other) activities: CMO (Contract Manufacturing) Biopharmaceuticals CDM (Contract development) Biopharmaceuticals QC (microbiolgical release testing) R&D activities: NA Core technologies: Recombinant proteins antibodies Gene therapy vectors Categories of activity: Biotech company; Biotech support company; Production; R&D service; Other service; Drug discovery; Diagnostics and devices; Biomaterials;
Cerebricon Ltd. Microkatu 1, FIN-70210 Kuopio, Finland Web site: www.cerebricon.com Personnel: 24	Juha Yrjänheikki, CEO Phone: +358 17 368 0801 Fax: +358 17 368 0803 juha.yrjanheikki at cerebricon.com Patrick Sweeney, Director of Business Development Phone: +358 17 368 0801 Fax: +368 17 368 0803 patrick.sweeney at cerebricon.com	Production (and other) activities: Independent contract based research company providing specialized in vitro and in vivo brain disease models for testing and developing new pharmaceutical compounds for stroke, Alzheimer´s, Parkinson, Huntington, trauma, migraine etc. R&D activities: Development of models that are crucial for studying the efficiency of drugs, resolving the mechanisms action, searching new drug candidates for brain diseases, and screening for new drug targets. Fee-based services or shared R&D projects possible. Core technologies: Validated disease models with analysis methods ranging from molecular to functional and behavioral tests. Categories of activity: Biotech company; R&D; Drug discovery;
Culminatum Innovation Oy Ltd Innopoli, Tekniikantie 12, 02150 Espoo Web site: www.biobusiness.fi Founded: 1995 Personnel: 4 (2010)	Riikka Paasikivi, Program Director Phone: +358-50-5215944 Fax: +358-10 2178901 riikka.paasikivi at culminatum.fi	Production (and other) activities: Culminatum Innovation Oy Ltd is a development company owned by the Uusimaa Regional Council, the cities of Helsinki, Espoo and Vantaa, and the universities, polytechnics, research institutes and business community of Helsinki region. Culminatum Innovation manages the Centre of Expertise Programme within Helsinki Region covering nine cluster fields (period 2007 - 2013). One of them is HealthBIO - Health cluster, that promotes the creation of new business activities and the development of high-tech products and services in the field of biotechnology. Categories of activity: Other service;
Danisco Technology Center Sokeritehtaantie 20, FIN-02460 Kantvik, Finland Web site: www.danisco.com Personnel: 97	Nina Rautonen, Director, Bioscience Phone: Fax: nina.rautonen at danisco.com Pekka Piiroinen, Development Director Phone: Fax: pekka.piiroinen at danisco.com	Production (and other) activities: Production Food and feed ingredients, sweeteners and speciality carbohydrates. R&D activities: Gut microbiology and physiology and immunology, nutrition, gene technology, enzymology, fermentation, separation and process technology. Core technologies: Gene Technology, Separation Technology. Categories of activity: Biotech company; R&D; Agro; Enzymes;
Faron Pharmaceuticals Oy Ltd Web site: www.faronpharmaceuticals.com Founded: 2002 Turnover: EUR 0.16 million (2004) Personnel: 1 (2004)	Markku Jalkanen, CEO Phone: +358 40 520 6124 Fax: +358 2 478 8411 markku.jalkanen at faronpharmaceuticals.com	Production (and other) activities: Drug discovery and drug development services. R&D activities: Inflammation, Cancer, Traumas, Functional foods. Core technologies: Cell trafficking and adhesion (Clever, CD73, Vap-1, CD44v6), Biologically active GAGs, Farbetics, Tumobiotics. Categories of activity: Biotech company; Biotech support company; R&D; Other service; Drug discovery; Food and feed;
Fibrogen Europe Oy Viikinkaari 6, 00790 Helsinki, Finland Web site: www.fibrogeneurope.com Founded: 1995 Personnel: 2 (2009)	Dr Juha Koivurinta Phone: +358 9 563 73 221 Fax: +358 9 563 73 224 jkoivurinta at fibrogeneurope.com	Production (and other) activities: Pilot production of different collagen types. R&D activities: Development of different collagen types, mainly types I, II, III and different collagen fragments (gelatins) for pharmaceutical and medical device use. Core technologies: Production of stable recombinant human collagens and gelatin using the patented multi-gene technology. Categories of activity: Biotech company; Supplier; Biomaterials;
Finn-Medi Research Ltd Finn-Medi Science and Business Park Biokatu 12, FI-33529 Tampere, Finland Web site: www.finnmediresearch.com Founded: 1995 Turnover: EUR 2 million Personnel: 14	Matti Eskola, Managing Director Phone: +358 3 3116 4020 Fax: +358 3 3116 4029 matti.eskola at finnmedi.fi Tiina Kärjä-Lahdensuu, Research Manager Phone: + 358 3 3116 4034 Fax: + 358 3 3116 4029 tiina.karja-lahdensuu at finnmedi.fi	Production (and other) activities: Finn-Medi Research offers expertise and services for health and biotechnology companies, researchers and pharmaceutical industry. Customers represent from biotechnology start-ups up to major pharmaceutical companies. Services include clinical trials (phase I-IV), business development and licensing, R&D consulting and project management. Finn-Medi Research also coordinates biotechnology development programs such as BioneXt Tampere and Centre of expertise programme. Bionext Tampere is 100 milion investment and development programme that focuses on immunology and vaccines, biomaterials and tissue technology and applied information technologies. Categories of activity: Biotech support company; Biotech centre; R&D service; Other service;
Finnfeeds Finland Ltd (trading as Danisco Animal Nutrition) Sokeritehtaantie 20, FIN-02460 Kantvik, Finland Web site: animalnutrition.danisco.com Founded: 1998 Turnover: EUR 35 million Personnel: 80	Juhani O. Kuusisto, Managing Director Phone: +358 10 4314686 Fax: +358 10 4314333 juhani.kuusisto at danisco.com	Production (and other) activities: Production Production facility in Naantali producing betaine and other molasses based fine chemicals. Core technologies: Cromatographic separation. Categories of activity: Biotech company; Production; Food and feed; Enzymes;
Finnfeeds Ltd (trading as Danisco Animal Nutrition) PO Box 461, FIN-65101 Vaasa, Finland Web site: animalnutrition.danisco.com Founded: 1991 Turnover: EUR 35 million Personnel: 16	Juhani O. Kuusisto, Managing Director Phone: +358 10 4314686 Fax: +358 10 4314333 juhani.kuusisto at danisco.com Rainer Skinnar, Plant Manager Phone: +358 10 4313508 Fax: +358 10 4313500 rainer.skinnar at danisco.com	Production (and other) activities: Production Production facility in Vaasa producing feed enzymes. Categories of activity: Biotech company; Production; Food and feed; Enzymes;
Finnish Red Cross Blood Service Kivihaantie 7, FIN-00310 Helsinki, Finland Web site: www.veripalvelu.fi Founded: 1947 Turnover: EUR 70 million (2005) Personnel: 500 (2005)	Jukka Partanen, Research Director Phone: +358 9 5801298 Fax: +358 9 5801429 jukka.partanen at veripalvelu.fi	Production (and other) activities: Blood and blood-related products; laboratory service for organ and stem cell transplantation; laboratory services related to haemostasis, coagulation and blood grouping. R&D activities: Stem cells; tissue banking; services for organ and stem cell transplantation. Core technologies: In R&D: Cell and molecular biology; genomics and genetics; Categories of activity: Biotech company; R&D; Other service;
Finnzymes Oy Keilaranta 16 A, FI-02150 Espoo, Finland Web site: www.finnzymes.com Founded: 1986 Personnel: 89 (2009)	Pekka Mattila, CEO Phone: +358 9 2472 3010 Fax: +358 9 2472 3200 fz at finnzymes.fi	Production (and other) activities: Thermostable DNA polymerases, other enzymes for molecular biology, PCR instruments and consumables, PCR-based diagnostics. Core technologies: PCR, diagnostics. Categories of activity: Biotech company; Production; R&D; Supplier; Diagnostics and devices; Enzymes;
FIT Biotech Oy Biokatu 8, FI-33520 Tampere, Finland Web site: www.fitbiotech.com Founded: 1995 Personnel: 37 (2008)	Kalevi Reijonen, CEO & President Phone: +358 33138 7000 Fax: +358 3 3138 7050 kalevi.reijonen at fitbiotech.com	Production (and other) activities: FIT Biotech Plc is an innovative medical biotechnology company engaged in the development and commercialization of its proprietary Gene Transport Unit (GTU®) technology and GTU product applications in DNA vaccination and immune therapy. The company's other areas of expertise are artificial immunogen, recombinant protein and antibody technologies, as well as GMP grade process development and production of DNA vaccines. In addition, the company has developed and launched test kits for the detection of natural latex allergens. FIT Biotech was established in 1995 and is located in Tampere, Finland, with operations also in Tartu, Estonia. R&D activities: Leveraging its GTU technology platform, FIT Biotech has built a strong product pipeline that comprises a therapeutic HIV vaccine, a preventive HIV vaccine, as well as vaccines for melanoma, diabetes and hepatitis C. FIT Biotech's HIV vaccine programs have already progressed to the Phase I/II stage. Core technologies: GTU technology: applicable to DNA vaccination as well as to immuno and gene therapies for the modulation of the immune system via antigens or cytokines for use in the treatment of infectious diseases, cancer and allergies. Categories of activity: Biotech company; Production; R&D; R&D service; Supplier; Drug discovery; Diagnostics and devices;
Foodfiles Oy Ltd Neulaniementie 2 L 6, FI-70210 Kuopio, Finland Web site: www.foodfiles.com Founded: 1998 Personnel: 10 (2004)	Dr Essi Sarkkinen, Managing and Research Director Phone: +358 17 288 1261 and Fax: +358 17 288 1269 essi.sarkkinen at foodfiles.com Ms Pirjo-Leena Kinanen-Nimmrichter, Administrative Manager Phone: +358 17 288 1270 and Fax: +358 17 288 1269 pirjo-leena.kinanen-nimmrichter at foodfiles.com	R&D activities: Clinical studies for food and pharmaceutical industry, regulatory affairs (food, food ingredients) for food industry, consultation in nutrition and health claims. Categories of activity: Biotech support company; R&D service; Food and feed;
Galilaeus Oy Kairiskulmantie 10, PO Box 113, FI-20781 Kaarina, Finland Web site: www.galilaeus.fi Founded: 1994 Personnel: 27 (2005)	Kristiina Ylihonko, CEO Phone: +358 2 274 1450 Fax: +358 2 273 1460 kristiina.ylihonko at galilaeus.fi	Production (and other) activities: Contract manufacturing of New Chemical Entities (NCE's) and small volume intermediates or on-market active ingredients. Galilaeus has GMP compliant fermentation facility for the manufacture of small molecule pharmaceuticals, also cytostatics. Process development for small molecule fermentation including strain construction/improvement, optimisation of fermentation conditions, downstream development, scale-up. R&D activities: Development of highly efficient fermentation processes for technologically demanding active pharmacetical ingredients and NCE's. Core technologies: Control of biosynthetic pathways in microbes by genetic engineering. Natural products chemistry. Categories of activity: Biotech company; Biotech support company; Production; R&D;
Genencor International Oy PO Box 13, FIN-42301 Jämsänkoski, Finland Web site: www.genencor.com Founded: 1990 Turnover: EUR 62 million Personnel: 200	Jouni Viljanen Phone: +358 14 7494 400 Fax: +358 14 7494 410 jviljanen at genencor.com Aino Mansikkamäki Phone: +358 19 2804 300 Fax: +358 19 2804 307 amansikkamaki at genencor.com	Production (and other) activities: Production Industrial enzymes and industrial fermentations. Core technologies: Manufacturing of industrial enzymes. Categories of activity: Biotech company; Production; Enzymes;
Genolyze Ltd PO Box 140, FIN-20521 Turku, Finland Web site: www.genolyze.com Founded: 2003 Personnel: 7	Marko Mäenpää, CEO Phone: +358 50 4616530 Fax: +358 10 633 8189 marko.maenpaa at genolyze.com	Production (and other) activities: Genolyze is bioinformatics research Service Company specializes in enhancing research, development and production processes by applying Bio-IT know-how. Company’s mission is to save researchers time and grow the value of measured data by revealing the useful information hidden into the massive data and complex multivariable studies. R&D activities: Computational methods for biological data, Biomarkers, Biological data management Core technologies: Sophisticated data analysis and computational methods, Mathematical and statistical modelling, Data management, IT and Bio-database systems. Categories of activity: Biotech company; Biotech support company; R&D service; Other service; Bioinformatics;
Headman Ltd Porttitie 11 D, FIN-02180 Espoo, Finland Web site: www.headman.fi Founded: 1992 Personnel: < 10	Klaus Hedman, MD, Professor Phone: +358 50 5249 086 Fax: klaus.hedman at helsinki.fi	Production (and other) activities: Diagnostics for infectious diseases. R&D activities: Diagnostics for infectious diseases; outsourced R&D; diagnostic consultation. Core technologies: IgG-avidity and epitope-type specificity serodiagnostics; other innovative antibody-EIA techniques; recombinant protein expression; molecular biology; quantitative PCR. Categories of activity: Biotech company; R&D; Diagnostics and devices;
Helsinki Business and Science Park Ltd Viikinkaari 4, FI-00790 Helsinki, Finland Web site: www.hbsp.net Founded: 1992 Turnover: EUR 2,8 million Personnel: 15 (2008)	Pia Westerling Phone: Fax: Antti Sekki, Business Development Director Phone: +358 9 319 36 543 Fax: +358 9 319 36 554 antti.sekki at hbsp.net	Production (and other) activities: Helsinki Business and Science Park (HBSP) provides a dynamic business environment with a diversified research and expert network and a Centre of Expertise within food technology, biotechnology, drug development and diagnostics, as well as environmental technology. HBSP operates in two campuses within the City of Helsinki, in Viikki Biocampus and in Meilahti Medical Campus. Categories of activity: Biotech centre; Other service;
Histola Research Oy Niittyhaankatu 20, FI-33720 Tampere Web site: www.histola.com Founded: 2004 Personnel: 10 (2008)	Pia Kivijärvi, Managing Director Phone: +358 20 7432 007 Fax: +358 20 7432 001 pia.kivijarvi at histola.fi Katja Veneskoski, Laboratory Manager Phone: +358 20 7432 002 Fax: +358 20 7432 001 katja.vaneskoski at histola.fi	Production (and other) activities: Histola Research Ltd is a contract research organization that offers testing and tailored experts services for non-clinical operations. Histola is having GLP accredited laboratory premises. Our services covers from research planning to practical arrangements and project management. We are committed to long term high quality co-operation and cost-efficient expertise in the implementation of non-clinical operations. • IN VITRO TOXICOLOGY AND CELL BIOLOGICAL RESEARCH • HISTOTECHNOLOGY (Immunohistochemistry) • ENVIRONMENTAL RESEARCH, ECOTOXICITY TESTING AND CONSULTANCY • NANOSAFETY • CHEMICAL TESTING (REACH) AND CONSULTANCY • PROJECT MANAGEMENT SERVICES AND CONSULTANCY Categories of activity: Biotech support company; R&D; R&D service; Other service; Supplier; Drug discovery; Diagnostics and devices; Biomaterials; Bioinformatics; Environment;
Hormos Medical Corp. - a subsidiary of QuatRx Pharmaceuticals Company USA Itäinen Pitkäkatu 4, FIN-20520 Turku, Finland Web site: www.hormos-med.com Founded: 1997 Turnover: EUR 2 million (2004) Personnel: 38 (2004)	Dr Risto Lammintausta, CEO Phone: +358 2 410 8000 Fax: +358 2 410 8001 risto.lammintausta at hormos-med.com	Production (and other) activities: QuatRx Pharmaceuticals Company, a biopharmaceutical company, focuses on research and development of therapeutic compounds primarily for the treatment of major endocrine, metabolic and cardiovascular diseases, especially dyslipidemia and endocrine diseases of aging. QuatRx has its headquarters in Ann Arbor, Michigan, with a significant presence in Europe through Hormos Medical Corp., a wholly-owned subsidiary of QuatRx Pharmaceuticals Company. R&D activities: The research activities of the company are based on its expertise in tissue-specific steroid hormone effects at the molecular and cellular level. Currently running projects in the indication areas of menopausal symptoms, androgen deficiency disorders, dyslipidemia. Core technologies: The company's core technologies include selective estrogen receptor modulators (SERM), selective androgen receptor modulators (SARM) and hydroxysteroid dehydrogenase (HSD) inhibitors. Categories of activity: Biotech company; R&D; Drug discovery;
Hytest Ltd. PharmaCity, Itäinen Pitkäkatu 4C, FI-20520 Turku, Finland Web site: www.hytest.fi Founded: 1994 Turnover: EUR 3,2 million (2003) Personnel: 24 (2003)	Jukka Lehikoinen Phone: +358 2 512 0900 Fax: +358 2 512 0909 jukka.lehikoinen at hytest.fi Susanna Brink Phone: +358 2 512 0900 Fax: +358 2 512 0909 susanna.brink at hytest.fi	R&D activities: HyTest is continuously working to bring new products to the market as well as improving the existing ones through R&D. Our R&D specialists maintain close ties with the scientific community and engage in joint research with the Finnish academic diagnostic research organizations. Core technologies: HyTest has become a leading supplier of several reagents worldwide (such as antibodies and antigens of the troponin complex or native human thyroid peroxidase), at the same time maintaining a broad range of other products. Categories of activity: Biotech company; Production; R&D; Diagnostics and devices;
Inion Oy Lääkärinkatu 2, FI-33520 Tampere, Finland Web site: www.inion.com Founded: 1999 Personnel: 95 (2004)	Chris Lee, CEO Phone: +44 (0) 1483 685 390 Fax: chris.lee at inion.com Julien Cotta, CFO Phone: +44 (0) 1483 685 390 Fax: julien.cotta at inion.com	Production (and other) activities: Inion is dedicated to developing and manufacturing novel medical devises based on innovative biomaterials. Inion developed solutions feature a range of proprietary technologies and processes that offer significant benefits over alternative methods and have won a growing number of the customers around the world. Priority is given to solutions that can be used quickly and easily, save valuable OR time and are priced competitively. Inion's product range includes biodegradable products for the following surgical applications: Craniomaxillofacial (Inion CPS), Orthopaedics (Inion OTPS), Sports medicine (Hexalon, Trinion) and dental (Inion GTR membrane). R&D activities: Inion's material and product testing is carried out at the company's special R&D laboratory at the headquarters, equipped with state-of-the-art manufacturing, laboratory and office facilities as well as class 10 000 clean room. Materials analysis work is also carried here, and at the reasearch centres and universities around the world. Core technologies: Polymer science and processing technology are the core technologies of Inion. Categories of activity: Biotech company; Production; R&D; Biomaterials;
Innomedica Oy Tykistökatu 6 B (BioCity), FI-20520 Turku, Finland Helsinki office: Tukholmankatu 8 B FIN-00290 Helsinki, Finland Web site: www.innomedica.fi Founded: 1997	Tanja Dowe, Managing Director Phone: +358 400 636 107 Fax: +358 2 2748 420 innomedica at innomedica.fi	Production (and other) activities: Innomedica is a service provider for the Life Science industry. Our main service products are: Japan Partnering, Project Management Services, Business Development, Internationalisation. Using our experienced team of Life Science Professionals, we can help our clients to get the best our of their technologies and product ideas. Innomedica is your Partner in Life Sciences. Categories of activity: Biotech support company; Other service;
Kuopio Innovation Ltd. PO Box 1188, Microkatu 1, FIN-70211 Kuopio, Finland Web site: www.kuopioinnovation.fi Founded: 2008 Turnover: EUR 2,3 million (2008) Personnel: 20	Heikki Nuutinen, Managing Director Phone: +358 500 674 413 Fax: +358 17 441 2011 heikki.nuutinen at kuopio.fi	Production (and other) activities: Kuopio Innovation Ltd. helps local technology enterprises develop domestic and international business activity. It promotes cooperation between business and research aiming to the creation of new business activities. The focus of operation is in the fields of health, environment and wellbeing. The core of the operation is the Centre of Expertise Programme and its related development projects. More information: www.kuopioinnovation.fi. Categories of activity: Biotech support company; Biotech centre; R&D service;
Licentia Ltd Tukholmankatu 8 A, FI-00290 Helsinki, Finland Web site: www.licentia.fi Founded: 2001 Turnover: EUR 1,5 million (2004) Personnel: 7		Production (and other) activities: Commercialization of research results and technologies (.Technology transfer). Technology and IP consulting. Categories of activity: Biotech support company; Other service; Drug discovery; Diagnostics and devices; Bioinformatics; Food and feed; Research reagents;
Magnasense Ltd Nanoscience Center, Survontie 9, FI-40500 JKL, Finland Web site: www.magnasense.com Founded: 2003 Personnel: 5	Mika Laitinen, CEO Phone: +358 40 5435989 Fax: mika.laitinen at magnasense.com Jari Salmela, R&D Manager Phone: Fax: jari.salmela at magnasense.com	R&D activities: Development of magnetometric lateral flow assay reader is going on. Magnasense also participates several research projects in the areas of magnetic particles and microfluidistics. Core technologies: Magnasense technology is based on the use of magnetic microspheres as labels and on the measurement of change on magnetization in the capture zone of a test. The diagnostic measuring instrument forms an easy to use quantitative biosensor when combined with disposable test cartridges. Either traditional sandwich assay or competitive assay formats can be used to form the capture zone. Detection method is suitable for e.g. proteins, steroids, drugs of abuse, nucleic acids, bacteria and viruses. Categories of activity: Biotech company; R&D service; Supplier; Diagnostics and devices;
Medeia Therapeutics Oy Microkatu 1, FI-70211 Kuopio, Finland Web site: www.medeiatherapeutics.com Founded: 2006	Milla Koistinaho, CEO Phone: +358-44-590 0603 Fax: +358-44-659 00603 milla.koistinaho(at)medeiatherapeutics.com	R&D activities: Medeia is engaged in the discovery and early development of novel therapies for diseases of the central nervous system. Categories of activity: Biotech company; R&D; Drug discovery;
Medical Interscience Talents M.I.T. Consulting Ltd Mannerheimintie 12 B, 5th floor, Helsinki PO Box 16, FI-00601 Helsinki, Finland Web site: www.mitconsulting.fi Founded: 1990 Turnover: EUR 0,2 million (2005) Personnel: 4 (2009)	Esa Soppi, President, CEO Phone: + 358 40 524 2728 Fax: + 358 9 728 7064 esa.soppi at mitconsulting.fi	Production (and other) activities: Medical Interscience Talents M.I.T. Consulting Ltd “Doing things that stand viewing and reviewing in the arena of life sciences” provides services creating of added business value and hands on operational execution, as well as state of art methodology and innovative customized solutions to resolve challenging customer problems. Strategy & operations: 1) Strategy audit & strategy development, 2) Portfolio and project assessment & value maximation, 3) Research & opportunity assessment, 4)Operative performance& process excellence. Development services: 1) Refinement of drug & device development process, 2) Risk assessment & management, 3) CRO & central laboratory contracting, 4) SOP management process. Core technologies: Proprietary methodology for portfolio management and valuation/value creation. Categories of activity: Biotech support company; R&D service;
Medipolis GMP Oy Kiviharjuntie 2, FI-90220 Oulu, Finland Web site: www.medipolisgmp.com Founded: 2001 Turnover: EUR 1 million Personnel: 15 (2005)	Dr. Ashesh Kumar, Director Phone: +358 400 207 380 Fax: kumar.ashesh at medipolisgmp.com	Production (and other) activities: Medipolis GMP Ltd is a CMO that offers process development, fermentation, downstream and spporting QA / QC services for companies that need manufacturing of biopharmaceuticals for preclinical, clinical trials and even commercial purposes. We are looking for parters in EU for FP-7 program and offer our excellent team for process development and GMP material production for Clinical studies R&D activities: BioPAT- Process Development, Clinical Development of Biopharmaceuticals Core technologies: Microbial fermentation with related process development and downstream processes. Categories of activity: Biotech company; Production;
Mobidiag Oy Tukholmankatu 8 (Biomedicum 2), FI-00290 Helsinki, Finland Web site: www.mobidiag.com Founded: 2000 Personnel: 18 (2010)	Aleksi Soini, CEO Phone: +358 9 191 25021 Fax: +358 9 191 25020 aleksi.soini at mobidiag.com Sari Valasti, Office Manager Phone: +358 9 191 25021 Fax: +358 9 191 25020 sari.valasti at mobidiag.com	Production (and other) activities: Mobidiag´s core products are DNA biochips for the rapid identification of important microbial pathogens directly from patient samples. R&D activities: Mobidiag is developing solutions for the user-friendly and cost-effective analysis of biochip test results. Core technologies: Mobidiag´s technology uses a patented univelsal approach to identify microbial species. This technology allows the rapid simultaneous detection of a large panel of organisms from a single sample. Categories of activity: Biotech company; R&D; Diagnostics and devices; Bioinformatics;
Novagenesis Oy Biomedicum Helsinki 2 U, Tukholmankatu 8, FIN-00290 Helsinki, Finland Founded: 2006 Personnel: 9 (2009)	Kauko Kurkela, Managing Director Phone: +358 50 310 6848 Fax: +358 10 440 5401 kauko.kurkela at novagenesis.fi	R&D activities: The Company specializes in the development of unique regeneration products for nervous system. Categories of activity: Biotech company; R&D; Diagnostics and devices;
Novamass Ltd Kiviharjuntie 11, FIN-90220 Oulu, Finland Web site: www.novamass.net Founded: 2002 Personnel: 11 (2009)	Jouko Uusitalo, CEO Phone: +358 207 639 669 Fax: +358 207 639 660 jouko.uusitalo at novamass.net	Production (and other) activities: We provide ADME contract research for drug discovery and development. Our core competences are in vitro drug metabolism studies (metabolic stability and metabolite identification), metabolism related drug interaction studies, and permeation studies of NCEs and related pharmacology. We also provide custom analysis based on LC/MS and NMR techniques and quantitative bioanalysis (eg. in vivo animal DMPK studies). R&D activities: Our services include metabolic stability, metabolite identification, metabolizing CYP enzyme identification, CYP inhibition and induction, cell line permeation, BBB penetration and in vivo metabolism studies. Our studies predict in vivo ADME properties of NCEs in man and are used to lead optimisation and selection of candidate drugs. Core technologies: Human and animal liver preparations. Determination of physicochemical ADME parameters, protein binding and permeability. Chemical purity and degradation. Liquid Chromatography combined with Mass Spectrometry (LC/MS), NMR. Analytical method development and validation. Bioanalysis. Categories of activity: Biotech support company; R&D service; Drug discovery;
Onbone Oy Linnoitustie 4 A, 02600 Espoo, Finland Web site: www.onbone.com Founded: 2008	Petro Lahtinen, CEO Phone: +358 50 5811033 Fax: petro.lahtinen (at) onbone.com	Production (and other) activities: Onbone commercialises and markets innovative proprietary medical devices used in the field of orthopaedic and traumatology treatments R&D activities: Onbone relies on constant product development and innovation of new solutions in order to fulfill user demands Core technologies: Biopolymers, composite biomaterials Categories of activity: Diagnostics and devices; Biomaterials;
Orion Corporation Orion Pharma Orionintie 1 A, PO Box 65, FI-02101 Espoo, Finland Web site: www.orionpharma.com Founded: 1917 Turnover: EUR 641,1 million (2006) Personnel: 3 061 (total) (2006)	Matti Vaheri, Director, CNS Business Phone: +358 10 4261 Fax: +358 10 426 3815 matti.vaheri at orionpharma.com Reijo Salonen, Senior Vice President, Research & Development Phone: +358 10 4261 Fax: +358 10 426 3600 reijo.salonen at orionpharma.com	Production (and other) activities: Production pharmaceuticals, active pharmaceutical ingridients and diagnostic point of care -test systems. R&D activities: Drug discovery and development on three core therapeutic areas: CNS, cardiovascular diseases and critical care, hormone replacement therapies and urology, as well as animal health. Core technologies: All major techniques for drug development from molecule to market. Categories of activity: Biotech company; Production; R&D; Drug discovery; Diagnostics and devices;
Orion Diagnostica Oy PO Box 83, FI-02101 Espoo, Finland Web site: www.oriondiagnostica.fi Founded: 1974 (as an independent divisi Turnover: EUR 39,3 million (2004) Personnel: 318 (2004)	Jaakko Rissanen, President Phone: + 358 10 429 4858 Fax: + 358 10 429 2794 jaakko.rissanen at oriondiagnostica.fi	Production (and other) activities: Production, sales and marketing of Diagnostic tests and test systems, monoclonal antibodies, protein purifucation and modification, dip-slide manufacturing, Large scale antibody production (poly and mono), Microparticles. R&D activities: Focusing on point of point-of-care test systems and special analytes: H. pylori, CRP, bone markers, anemia markers, steroid hormones. Core technologies: Analyte know-how, Multiple assay technologies, Microparticle technology. Categories of activity: Biotech company; Production; R&D; Supplier; Diagnostics and devices;
Oulu Innovation Oy / Bio Forum Oulu Elektroniikkatie 6, FI-90570 Oulu, Finland Web site: www.ouluinnovation.com Founded: 2004	Olli Löytynoja, Vice President Phone: +358 8 551 3005 Fax: +358 8 551 3627 olli.loytynoja at ouluinnovation.com Tuula Palmén, Program Director Phone: +358 50 461 7290 Fax: +358 207 545 879 tuula.palmen at bioforumoulu.org	Production (and other) activities: Development projects within Life Sciences incl. biotechnology. The convergence of BIO with Nano, IT and Eco. Categories of activity: Biotech support company; Other service;
PerkinElmer Wallac Oy Mustionkatu 6, FIN-20101 Turku, Finland Web site: www.perkinelmer.com Founded: 1950 Turnover: EUR 100 million Personnel: 650	Hanna Halme, General Manager Phone: +358 2 267 8339 Fax: +358 2 267 8357 hanna.halme at perkinelmer.com Kauko Lamminpää, Sales Manager Phone: +358 2 267 8464 Fax: +358 2 267 8305 kauko.lamminpaa at perkinelmer.com	Production (and other) activities: Production Final assembly and testing of instruments, reagent production and labelling service. R&D activities: Research of new technologies related to genetic screening and drug discovery applications. Product development regarding total solutions including instrumentation, chemistry and software. Applications for clinical diagnostics, bioanalytical research and drug discovery. Categories of activity: Biotech company; Production; R&D; Diagnostics and devices;
Reagena Oy Ltd Takojantie 18, FI-70900 Toivala, Finland Web site: www.reagena.fi Founded: 1987 Turnover: EUR 1,3 million (2008) Personnel: 16 (2008)	Dr Markku Parviainen, PhD, Managing Director, CEO Phone: +358 17 368 8504 Fax: +358 17 368 8530 markku.parviainen at reagena.fi Ms Kati Ryynänen, MSci, Marketing Manager Phone: +358 17 368 8505 Fax: +358 17 368 8530 kati.ryynanen at reagena.fi	Production (and other) activities: Production of in vitro diagnostic (IVD) products such as biological staining solutions and test kits. Manufacturer of ReaMobile™ point-of-care diagnostic system with different POC tests. Reagents according to Ph.Eur. Along with the product line of high quality liquid-based reagents, we are engaged in contract development and production for other industries. We supply liquid-based reagents and solutions to our industrial partners as contract manufacturer. R&D activities: Point-of-care testing (R&D, manufacturing, commercialisation of innovations). Core technologies: New ReaMobile™ Test System is based on REASCAN™ rapid test reader with ReaLink™ Bluetooth device and ReaMobile™ software on a mobile phone or a PC, and our new proprietary immuno-chromatography technology. The ReaMobile™ test system is versatile for quantitative and qualitative applications in clinical chemistry, virology, and microbiology. Categories of activity: Biotech company; Production; R&D; R&D service; Supplier; Diagnostics and devices; Research reagents;
Roal Oy PO Box 57, Tykkimäentie 15, FI-05201 Rajamäki, Finland Web site: www.roal.fi Founded: 1992 Turnover: EUR 33 million (2007) Personnel: 102 (2009)	Pekka Kekki, Managing Director Phone: +358 9 29042 140 Fax: +358 9 29042 114 pekka.kekki at roal.fi Jari Vehmaanperä, Research Director Phone: +358 9 29042 120 Fax: +358 9 29042 112 jari.vehmaanpera at roal.fi	Production (and other) activities: Industrial enzymes for food, feed, beverage, textile, detergent and P&P applications. R&D activities: Discovery and cloning of novel enzymes for existing and new applications. Strain improvement and process development. Core technologies: Trichoderma production technology. Industrial enzymes (particularly cellulases and hemicellulases). Categories of activity: Biotech company; Production; R&D; Supplier; Enzymes;
Syngenta Crop Protection A/S Finnish subsidiary PO Box 124, FI-10301 Karjaa, Finland Web site: www.syngenta.com Founded: 2001	Risto Knaapinen, Business manager Phone: + 358 19 236 106 Fax: + 358 19 236 108 risto.knaapinen at syngenta.com Arto Markkula, Crop Manager Phone: + 358 2 436 7151 Fax: + 358 2 436 7161 arto.markkula at syngenta.com	Production (and other) activities: Marketing Crop Protection products. R&D activities: Development in the field of crop protection and seeds. Categories of activity: Biotech support company; Supplier; Agro;
Systems Biology Worldwide Oy Mikonkatu 8, FI-00100 Helsinki Web site: www.systemsbiology.fi Founded: 2007	Juho Eväsoja, CEO Phone: +358 40 730 2313 Fax: +358 9 678 783 juho.evasoja at systemsbiology.fi Juha Saharinen, CTO Phone: +358 40 528 1973 Fax: +358 9 678 783 juha.saharinen at systemsbiology.fi	Production (and other) activities: We offer services in the area of: * Efficacy studies * In vitro ADMET * Safety studies * In vivo PK and bioanalytics * Discovery informatics Categories of activity: Biotech support company; R&D service; Drug discovery; Bioinformatics;
Ternics Oy Riitankuja 7 A 11, FI-00840 Helsinki, Finland Web site: www.ternics.com Founded: 1993 Personnel: 1 (2005)	Erkki Tikkanen, CEO Phone: +358 9 6987 087 Fax: +358 9 6228 0332 tikkanen at ternics.inet.fi	Production (and other) activities: Management consulting, business and financing plans, numerical and investment analysis, acquisitions etc for health care and life science companies. Strategy studies and portfolio analysis for Public Actors and Life Science Centers and Venture Capital companies. Categories of activity: Biotech support company; Other service; Drug discovery; Diagnostics and devices; Biomaterials; Bioinformatics; Food and feed; Agro; Environment; Enzymes; Research reagents;
Turku Science Park Oy / BioTurku / HealthBIO Itäinen Pitkäkatu 4 B, FIN-20520 Turku, Finland Web site: www.turkusciencepark.com Founded: 1988 Turnover: EUR 7 million Personnel: 40	Tero Piispanen, Program Director Phone: +358 400 781 683 Fax: +358 2 4101 830 tero.piispanen at turkusciencepark.com	Production (and other) activities: Turku Science Park Ltd coordinates the activity of the regional BioTurku® cluster as well as the national HealthBIO network covering the five majour Finnish regional bioclusters within the new Centre of Expertise Programme 2007-2013. BioTurku® is the cluster of biotech actors in the Turku region including about 90 biotechnology companies, 2 universities as well as several educational and research institutes. Turku Science Park Ltd coordinates the development of the BioTurku® cluster, offers various services for the bio community and premises for national and international life science companies – with the goal to increase entrepreneurship in the Turku region.The focus areas of BioTurku are drug discovery, development and release, diagnostics and biomarker development. The three therapeutic focus areas are cancer and hormonal diseases, inflammatory and infectious diseases and diseases of the CNS. Regional strengths are preclinical and clinical research, bioimaging platform from cell to body and biomaterials. The HealthBIO work programme focuses on health-related biotechnology and associated business areas http://www.healthbio.fi Categories of activity: Biotech centre; Other service;
Verdera Oy PO Box 5 (Kurjenkellontie 5 B), FI-02271 Espoo, Finland Web site: www.verdera.fi Founded: 2002 Personnel: 13 (2007)	Nils-Johan Grönholm, Managing Director Phone: +358 10 217 3730 Fax: +358 10 217 3711 njgronholm at lallemand.com Heli Hynynen, Assistant Phone: +358 10 217 3720 Fax: +358 10 217 3711 hhynynen at lallemand.com	Production (and other) activities: Developes, produces and markets biological pesticides and growth promoters used in forestry, horticulture, turf and amenity. R&D activities: Control of soil-borne as well as foliar plant diseases, process development of the production of biofungicides. Core technologies: Control of plant diseases by microorganisms, formulation techniques for microorganism. Categories of activity: Biotech company; Production; R&D; Agro;